Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection.
about
Structural Engineering of pMHC Reagents for T Cell Vaccines and DiagnosticsImmune Reconstitution after Allogeneic Hematopoietic Stem Cell TransplantationAnalytical performance of a standardized single-platform MHC tetramer assay for the identification and enumeration of CMV-specific CD8+ T lymphocytes.Improving cytomegalovirus-specific T cell reconstitution after haploidentical stem cell transplantationMonitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation.Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation.Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantationGlucocorticosteroids trigger reactivation of human cytomegalovirus from latently infected myeloid cells and increase the risk for HCMV infection in D+R+ liver transplant patients.Prevention and management of CMV-related problems after hematopoietic stem cell transplantation.Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemiaDecreased proportion of cytomegalovirus specific CD8 T-cells but no signs of general immunosenescence in Alzheimer's disease.Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samplesMaternal cytomegalovirus-specific immune responses and symptomatic postnatal cytomegalovirus transmission in very low-birth-weight preterm infantsPrevention of cytomegalovirus disease in recipients of allogeneic stem cell transplantsLarge scale analysis of pediatric antiviral CD8+ T cell populations reveals sustained, functional and mature responses.Immune reconstitution following haematopoietic stem cell transplantation.CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoireCMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.Clinical implications of T cell receptor repertoire analysis after allogeneic stem cell transplantation.No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies.Immune reconstitution following stem cell transplantation.Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy.Cellular immunotherapy for viral infection after HSC transplantation.Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies.Procedure for preparing peptide-major histocompatibility complex tetramers for direct quantification of antigen-specific cytotoxic T lymphocytesAcquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation.The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease.Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramersProtection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cellsCMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients.Regulating regulatory T cells.Immunology and immunotherapy approaches for prostate cancer.A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector.Vaccine strategies against human cytomegalovirus infection.Expansion of human cytomegalovirus (HCMV) immediate-early 1-specific CD8+ T cells and control of HCMV replication after allogeneic stem cell transplantation.Impairment of cytomegalovirus-specific cellular immune response as a risk factor for cytomegalovirus disease in transplant recipients.Immunobiology of human cytomegalovirus: from bench to bedside.Rapid reconstitution of CD4 T cells and NK cells protects against CMV-reactivation after allogeneic stem cell transplantation.Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients.
P2860
Q27647545-8DB361EA-EED9-4DCE-9EE8-270FFF65551DQ28072627-D718E149-2928-457C-8BEE-7D957918E456Q33369455-CD02C49E-1F32-48AD-AA11-9D0852437CF4Q33597783-3024545B-0620-45DB-896E-FE700D1756EAQ34358755-7F0DA752-0502-4731-A128-99A9B5E059AAQ34524941-A18EC69A-4502-4D1F-AD58-E1EC6BE12C52Q34649004-F6BB1F0C-78E2-4AEC-9474-BC93D6A11CABQ34720787-7DCFB73B-87B7-4F9C-AEBE-53A8D01B0D0AQ34785629-489DE2BA-E221-4967-BD2F-62C1418701A3Q34808353-731E31F1-41C1-432A-A526-5A445F0B1F15Q35025534-DBD31131-EA16-47DF-8109-352A58A2D713Q35223576-DE69DA4A-A1E6-465A-A228-1E28F3448CCBQ35463640-6F18AC59-F510-43FE-843B-0D06825E2FFDQ35558815-426251E7-29B4-49E9-90A6-FE49D32E8C7AQ35614110-8D33141E-74C3-49D3-8624-A6951BADD8FBQ35675862-3073F12B-9020-42A8-BA83-046549364751Q35757381-CEE21AD8-C604-4839-B8E8-53C4D980593AQ35776868-30A8578A-8018-45BF-8706-4D79FBF1A410Q35809452-015674C2-7E70-4BB3-BC56-4A3B1FE57B0BQ35880899-833715A4-E5D8-4BB2-9108-22C96896DC28Q35883820-129D969F-F908-4348-8980-96F626C004F3Q35917480-7222BFB9-9DE7-45A3-AED1-FBB788EC29D4Q35998792-9FD45E09-2538-4C74-986C-DAAF9630F60EQ36048199-D05A630D-B2C9-43FE-977A-5E1DAD089DA2Q36190463-52B7F7CF-75A0-4D2C-8B76-1D6B5C3DD946Q36228210-A6A49FD5-DADF-4B28-83D7-C020F59D1A0BQ36302615-4C506308-E6F9-4C2C-92EC-D6F937B6E63CQ36399914-32968AA1-40C5-411A-B37B-C8056CA99174Q36403280-E58DF148-A8E5-4AC7-BC31-6D23DB1F2D06Q36403419-7512F10E-7B05-433A-846B-02A8F0AB99C8Q36440010-8B894E4D-26A2-45DE-A951-408E8671E950Q36631649-AF4C0495-8EC6-45C9-A811-BA26135F871FQ36786512-8BB78249-EBC1-4233-88F6-7DB3AFBD75A6Q36824066-D007CB8B-6AA3-497F-B416-C2065BBD1EE7Q36839736-B660934E-A225-44DA-B71A-CC03BCE32863Q36933904-D18AD724-63C3-4880-8F32-77B3CF9E80E8Q37024817-907FDFFE-F4BE-410C-9CDA-9AD67025E842Q37050965-3E6A8B92-0B27-4873-B57D-C5316F8BAD3EQ37148363-5733693C-CE1C-4DB9-885F-B30AAA1ED880Q37262446-C2B6EFB5-F551-4019-92A4-DB5F39D36549
P2860
Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Tetramer-based quantification ...... for progressive CMV infection.
@en
Tetramer-based quantification of cytomegalovirus
@nl
type
label
Tetramer-based quantification ...... for progressive CMV infection.
@en
Tetramer-based quantification of cytomegalovirus
@nl
prefLabel
Tetramer-based quantification ...... for progressive CMV infection.
@en
Tetramer-based quantification of cytomegalovirus
@nl
P2093
P356
P1433
P1476
Tetramer-based quantification ...... for progressive CMV infection.
@en
P2093
Bolhuis RL
Cornelissen JJ
Gratama JW
Löwenberg B
van Esser JW
P304
P356
10.1182/BLOOD.V98.5.1358
P407
P577
2001-09-01T00:00:00Z